These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11463136)

  • 1. Perospirone.
    Onrust SV; McClellan K
    CNS Drugs; 2001; 15(4):329-37; discussion 338. PubMed ID: 11463136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent].
    Ohno Y
    Nihon Yakurigaku Zasshi; 2000 Oct; 116(4):225-31. PubMed ID: 11084919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perospirone in the treatment of patients with delirium.
    Takeuchi T; Furuta K; Hirasawa T; Masaki H; Yukizane T; Atsuta H; Nishikawa T
    Psychiatry Clin Neurosci; 2007 Feb; 61(1):67-70. PubMed ID: 17239041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Perospirone therapy in elderly patients with schizophrenia].
    Masui T; Honma H; Kondo C; Osawa T; Iwasaki S; Matsubara S
    Seishin Shinkeigaku Zasshi; 2003; 105(10):1247-53. PubMed ID: 14679781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Kishi T; Iwata N
    CNS Drugs; 2013 Sep; 27(9):731-41. PubMed ID: 23812802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of coprophagia in a patient with schizophrenia with the novel atypical antipsychotic drug perospirone.
    Harada KI; Yamamoto K; Saito T
    Pharmacopsychiatry; 2006 May; 39(3):113. PubMed ID: 16721701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perospirone in the treatment of schizophrenia: effect on verbal memory organization.
    Araki T; Yamasue H; Sumiyoshi T; Kuwabara H; Suga M; Iwanami A; Kato N; Kasai K
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):204-8. PubMed ID: 16300872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perospirone. SM 9018.
    Drugs R D; 1999 Aug; 2(2):142-3. PubMed ID: 10820662
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term perospirone treatment with a single dose at bedtime in schizophrenia: relevant to intermittent dopamine D2 receptor antagonism.
    Kusumi I; Masui T; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):520-2. PubMed ID: 18006133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of perospirone on auditory P300 in schizophrenia: a preliminary study.
    Araki T; Kasai K; Rogers MA; Kato N; Iwanami A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1083-90. PubMed ID: 16723179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two cases of perospirone-induced mania in schizophrenia.
    Yokoshima T; Takei N; Tani K; Kawai M; Minabe Y; Mori N
    J Clin Psychiatry; 2004 Jan; 65(1):135. PubMed ID: 14974495
    [No Abstract]   [Full Text] [Related]  

  • 16. Perospirone. SM 9018.
    Drugs R D; 1999 Jul; 2(1):60-2. PubMed ID: 10610286
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia.
    Kaneda Y; Kawamura I; Fujii A; Ohmori T
    Neuro Endocrinol Lett; 2004; 25(1-2):135-40. PubMed ID: 15159697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perospirone (Sumitomo Pharmaceuticals).
    de Paulis T
    Curr Opin Investig Drugs; 2002 Jan; 3(1):121-9. PubMed ID: 12054062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of perospirone for obesity and diabetes mellitus in patients with schizophrenia: three case reports.
    Nishida M; Nakamura M
    Int Clin Psychopharmacol; 2004 Jan; 19(1):41-3. PubMed ID: 15101570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent.
    Sakamoto H; Matsumoto K; Ohno Y; Nakamura M
    Pharmacol Biochem Behav; 1998 Aug; 60(4):873-8. PubMed ID: 9700971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.